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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
Vasopressin 
activates NCC by 
phosphorylation
While vasopressin is known for its antidiu-
retic effect, recent studies have implicated 
it in regulation of sodium absorption in 
the thick ascending limb and the distal 
convoluted tubule. In this issue, Pedersen 
et al. examine the role of this hormone 
in the regulation of the thiazide-sensitive 
Na+-Cl– cotransporter (NCC). Previous 
research has shown that NCC is phospho-
rylated on a number of threonine residues 
and that this phosphorylation increases 
the activity of the transporter. The authors 
demonstrated that vasopressin increases 
intracellular Ca in the distal convoluted 
tubule. Further, they developed new anti-
bodies that recognize phosphorylated 
NCC and found that addition of this hor-
mone caused phosphorylation of the api-
cal transporter in rats lacking vasopressin. 
The hormone also increased the activities 
of two kinases, SPAK and OSR1, previously 
known to phosphorylate this transporter. 
This pathway has been identified recently 
as one that regulates NaCl cotransport in 
response to angiotensin II, but it appears 
that vasopressin works on the same pathway 
through its own receptor. See page 160.
MYH9  mutations  
and FSGS
Recent genomic studies in a variety of renal 
diseases have identified encoding nonmus-
cle myosin heavy chain IIA (MYH9) as a 
critical protein that might be involved in 
chronic kidney disease, especially in African 
Americans. MYH9 is mutated in a number 
of hereditary syndromes characterized by 
anomalies in blood cells, such as macro-
thrombocytopenia, and by cytoplasmic 
inclusion bodies in granulocytes—May–
Hegglin anomaly, Sebastian syndrome, 
Epstein syndrome (EPS), and Fechtner 
syndrome (FTNS). Among these diseases, 
patients with EPS or FTNS develop pro-
gressive renal disease with hearing loss. 
Sekine et al. analyzed the clinical and path-
ological features of nine patients with EPS 
or FTNS who had mutations in MYH9 at 
the R702 codon, a hot spot for mutations. 
Most of the patients had proteinuria and/
or hematuria in early infancy and had a 
rapid progression of renal impairment 
during adolescence. Renal biopsy exami-
nation in one patient was compatible with 
focal segmental glomerulosclerosis (FSGS), 
and in that patient, there was less staining 
of MYH9 than in control biopsies. These 
studies establish the role of MYH9 in the 
development of FSGS. See page 207.
FGF23 and CKD  
in children
Fibroblast growth factor 23 (FGF23) is a 
critical protein, newly identified as reduc-
ing phosphate reabsorption in the kidney as 
well as inhibiting 1-α-hydroxylase and thus 
the production of active vitamin D. As they 
report in this issue, Van Husen et al. studied 
its levels in a large number of children with 
renal disease and found that, as with adults, 
the level of FGF23 is increased in renal fail-
ure. They also found that FGF23 progres-
sively became elevated as early as stage 3 
chronic kidney disease (CKD), before sig-
nificant hyperphosphatemia developed. 
Later stages of renal failure showed even 
greater elevation of the hormone. The levels 
of FGF23 correlated positively with parathy-
roid hormone and phosphate concentrations 
and negatively with 1,25-dihydroxyvitamin 
D, the estimated glomerular filtration rate, 
and tubular phosphate reabsorption. These 
findings are somewhat similar to those in 
adults. These studies provide a good baseline 
database from which to identify the role of 
FGF23 in renal osteodystrophy in children. 
See page 200.
